菜单

Webinar

WuXia293Stable for the Development and Manufacture of Difficult-to-Express Molecules
October 21, 2025
WuXia293Stable for the Development and Manufacture of Difficult-to-Express Molecules

Abstract:

 

Scientists typically use CHO cells to express antibody-based therapeutics and recombinant proteins. However, some proteins resist CHO expression, causing low titer, truncation, or non-human post translational modifications. The WuXia293Stable technology platform develops and manufactures of difficult-to-express proteins. Supporting high-quality cell line development, the platform delivers high titer, stability, and quality.

 

Watch the webinar on-demand and explore how WuXia293Stable:

 

  • Maintains high titers while eliminating or significantly alleviating truncation in complex molecules .
  • Achieves a fed-batch titer as high as 5 g/L for monoclonal antibodies while significantly improving purity.
  • Maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing.
    • Fed-batch operates at a 2,000 L scale.
    • Perfusion operates at a1,000 L scale.

 

Speakers:

Sam Zhang, PhD
VP of Biologics Development & Manufacturing

 

Watch On Demand